Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The user is concerned about having a straight, low hairline after a hair transplant and is unable to take finasteride due to high estrogen and prolactin levels. They have used minoxidil with limited success and are considering further transplants to lower the hairline, while others suggest the risks of using up donor hair too quickly.

Hope Medicine's HMI-115 is expected to be released in 2027, with phase 3 trials currently recruiting. Concerns include the safety of targeting prolactin and the potential cost of the treatment.

The user is experiencing hair loss despite using finasteride and minoxidil, possibly due to slight hypothyroidism and borderline vitamin D deficiency. They have started treating these conditions but have not yet seen improvement.

The conversation discusses HMI 115, a new hair loss treatment with promising results, showing a significant increase in hair density after two months. Some users are skeptical, while others are hopeful for its release and potential affordability.

Hair loss treatments include finasteride, minoxidil, and scalp exercises. Opinions vary on the effectiveness, with some attributing hair loss to muscle tension and inflammation, while others focus on genetics and DHT.

The conversation discusses using a Dermapen for hair loss treatment, with OP using depths of 1.5-2mm on the crown and less on the temples. OP is also taking oral Minoxidil 2.5mg and Finasteride 1mg, and applies Hyaluronic acid after treatment.

PP405 is criticized as ineffective compared to minoxidil and finasteride for treating hair loss. Users express skepticism about its potential, despite significant investment and claims of activating hair follicle stem cells.

Minokem-N's composition is unclear, with concerns about unlisted hydrocortisone. Users discuss alternatives like AloATM, which lacks soothing agents, and the challenges of verifying ingredients.

Low testosterone and estradiol may contribute to hair loss, and blocking DHT without sufficient hormone levels might hinder regrowth. The discussion highlights the importance of hormone balance, with some considering supplements and lifestyle changes to support hair health.

DUPA and retrograde alopecia may not be solely DHT-based, and a biopsy is crucial for accurate diagnosis and treatment. Treatments mentioned include dutasteride, oral minoxidil, pioglitazone, clobetasol, calcipotriol, ketoconazole, and doxycycline, depending on the specific condition.

Hope Medicine's announcement of the HMI-115 Phase II clinical trial for androgenetic alopecia in China; other related trials have been conducted or are ongoing in different countries, including Australia, US, and Europe. There is speculation that the product may be accepted across borders without additional testing.

The potential availability of a new hair loss treatment called HMI-115, which has shown promising results in experiments on monkeys but is not yet available to the public. Replies cautioned against using unproven substances from shady labs.

New hair loss treatments PP405 and VDPHL01 are discussed with skepticism and hope, alongside existing treatments like minoxidil and finasteride. Users express frustration over limited progress since the 1980s but remain cautiously optimistic.

The user experiences hypotension and sleepiness with topical minoxidil and is advised to consider alternatives like lowering the dose, using 2% minoxidil, or trying rosemary oil. They are also suggested to microdose oral minoxidil.

Men with hair loss might have lichen planopilaris (LPP), which can mimic androgenetic alopecia, leading to misdiagnosis and ineffective treatment with finasteride or dutasteride. Proper diagnosis, including biopsies, is crucial to distinguish between androgenetic alopecia and conditions like LPP.

A low carbohydrate diet may reduce DHT levels, potentially aiding hair loss prevention, but its effects on humans are uncertain. Some users argue that diet changes alone won't stop hair loss, and results from rodent studies don't necessarily apply to humans.

DHT negatively affects scalp hair while promoting body hair growth, causing frustration due to the lack of permanent solutions for baldness. Users discuss treatments like finasteride and potential future solutions like CRISPR technology.

The conversation discusses hair loss treatments, mentioning minoxidil, finasteride, RU58841, VDPHL, GT20029, and follicle cloning as potential solutions. It also reveals that the discussion about PP405 was an April Fool's joke.

PP405 is ineffective for miniaturized, fibrosed hair follicles in androgenetic alopecia. AMP303 may activate hair follicle stem cells, but minoxidil and finasteride are still the main treatments.

The conversation discusses HMI-115, a potential cure for hair loss. Users share mixed opinions, with some expressing skepticism and others sharing anecdotal evidence of its effectiveness, including photos of significant hair regrowth from a trial participant.

The conversation is about a person in their early 20s experiencing hair loss who stopped using Minoxidil due to side effects and is hesitant to try finasteride due to potential risks. They are considering waiting for a new treatment, pp405, despite its uncertainties and early testing stage.